Since the autocrine Gal-9 binding to TIM-3 on the surface of leukemic blasts drives the self-renewal of AML stem cells (11), it is a potential therapeutic strategy to block TIM-3 using anti-TIM-3 mAbs. Here, HAVCR2 is linked to acute myeloid leukemia.